Loading...
Humacyte, Inc.
HUMA•NASDAQ
HealthcareBiotechnology
$2.59
$-0.03(-1.15%)
Humacyte, Inc. (HUMA) Financial Performance & Statements
Review Humacyte, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
-14.34%
↓ 14.34%
Net Income Growth
100.00%
↑ 100.00%
Operating Cash Flow Growth
-33.85%
↓ 33.85%
Operating Margin
-1433.23%
↓ 1433.23%
Gross Margin
23.12%
↑ 23.12%
Net Profit Margin
-1002.79%
↓ 1002.79%
ROE
285.97%
↑ 285.97%
ROIC
-77.88%
↓ 77.88%
Humacyte, Inc. (HUMA) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Humacyte, Inc. stock.
Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
---|---|---|---|---|
Revenue | $7.23M | $0.00 | $0.00 | $0.00 |
Cost of Revenue | $3.61M | $0.00 | $1.82M | $1.79M |
Gross Profit | $3.61M | $0.00 | -$1.82M | -$1.79M |
Gross Profit Ratio | $0.50 | $0.00 | ||
R&D Expenses | $20.66M | $22.93M | $23.75M | $21.26M |
SG&A Expenses | $11.05M | $7.31M | $3.92M | $3.52M |
Operating Expenses | $31.70M | $30.23M | $27.68M | $24.79M |
Total Costs & Expenses | $35.32M | $30.23M | $29.50M | $26.58M |
Interest Income | $852000.00 | $911000.00 | $1.31M | $1.03M |
Interest Expense | $2.51M | $2.44M | $2.52M | $1.82M |
Depreciation & Amortization | $1.81M | $1.81M | $1.82M | $1.79M |
EBITDA | -$16.62M | -$30.23M | -$52.33M | -$28.29M |
EBITDA Ratio | -$2.30 | |||
Operating Income | -$28.09M | -$30.23M | -$29.50M | -$26.58M |
Operating Income Ratio | -$3.89 | |||
Other Income/Expenses (Net) | $7.15M | -$8.97M | -$27.16M | -$5.32M |
Income Before Tax | -$20.94M | -$39.20M | -$56.66M | -$31.90M |
Income Before Tax Ratio | -$2.90 | |||
Income Tax Expense | $0.00 | $0.00 | $0.00 | $1.75M |
Net Income | -$20.94M | -$39.20M | -$56.66M | -$31.90M |
Net Income Ratio | -$2.90 | |||
EPS | $1.08 | -$0.33 | -$0.48 | -$0.29 |
Diluted EPS | $1.08 | -$0.33 | -$0.48 | -$0.29 |
Weighted Avg Shares Outstanding | $118.48M | $119.41M | $119.17M | $108.25M |
Weighted Avg Shares Outstanding (Diluted) | $118.48M | $119.41M | $119.17M | $108.25M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan